Name | Tasosartan |
Synonyms | ANA-756 DB01349 AC1L1U5X AC1Q6LAA TASOSARTAN Tasosartan S1539_Selleck 2,4-Dimethyl-8-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-5,6-dihydropyrido[6,5-d]pyrimidin-7-one 5,8-Dihydro-2,4-dimethyl-8-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]pyrido[2,3-d]pyrimidin-7(6H)-one |
CAS | 145733-36-4 |
Molecular Formula | C23H21N7O |
Molar Mass | 411.46 |
Density | 1.328±0.06 g/cm3(Predicted) |
Melting Point | 197-199° |
Boling Point | 759.4±70.0 °C(Predicted) |
Solubility | DMSO (Slightly), Methanol (Slightly, Sonicated) |
Appearance | Solid |
Color | White to Off-White |
pKa | 4.16±0.10(Predicted) |
Storage Condition | 2-8°C |
In vitro study | Tasosartan is an orally active nonpeptide AngII antagonist that has demonstrates specific and selective AT1 receptor antagonistic activity in vitro. IC 50 for inhibition of specific binding of 125 I-AngII to rat adrenal membrane in the absence of proteins in binding buffer is 1.2±0.6 nM. |
In vivo study | Administration of Tasosartan at doses of 1.0 and 3.0 mg/kg (iv) significantly (p<0.05) attenuates the pressor response to angiotensin-II in rats. |